Enzyme 15-lipoxygenase 1 promotes hypoxia-inducible factor 1α turnover and reduces vascular endothelial growth factor expression: implications for angiogenesis

Hua Zhong1,2, Ruoxiang Wang1,3, Uddhav Kelavkar4, Christopher Y. Wang1 & Jonathan Simons1,5

1Department of Urology and Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322
2Rutgers Cancer Institute of New Jersey and Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901
3Uro-Oncology Research, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048
4Mercer University School of Medicine, 1550 College Street, Macon, Georgia 31207
5Prostate Cancer Foundation, 1250 4th Street, Santa Monica, California 90401

Keywords
15-lipoxygenase 1, HIF-1α, hypoxia, ubiquitination, VEGF

Abstract

Hypoxia-inducible factor 1α (HIF-1α) is the regulatory subunit of the heterodimeric HIF-1 that plays a critical role in transcriptional regulation of genes in angiogenesis and hypoxic adaptation, while fatty acid metabolism mediated by lipoxygenases has been implicated in a variety of pathogeneses, including cancers. In this study, we report that 15-lipoxygenase 1 (15-LO1), a key member of the lipoxygenase family, promotes HIF-1α ubiquitination and degradation. Altering the level of 15-LO1 yields inverse changes in HIF-1α and HIF-1 transcriptional activity, under both normoxia and hypoxia, and even in CoCl2-treated cells where HIF-1α has been artificially elevated. The antagonistic effect of 15-LO1 is mediated by the Pro564/hydroxylation/26S proteasome system, while both the enzymatic activity and the intracellular membrane-binding function of 15-LO1 appear to contribute to HIF-1α suppression. Our findings provide a novel mechanism for HIF-1α regulation, in which oxygen-dependent HIF-1 activity is modulated by an oxygen-insensitive lipid metabolic enzyme.

Introduction

The role of hypoxia-inducible factor 1α (HIF-1α) in cellular adaptation to hypoxia has been well established [1]. As the regulatory subunit of the heterodimeric HIF-1 transcription factor complex, HIF-1α turnover is finely tuned by intracellular and extracellular cues under normoxia to maintain homeostasis. This adaptive mechanism is frequently hijacked for the growth and survival of malignant cells, as evidenced by our previous finding that HIF-1α is abnormally activated in most types of cancer [2]. With the tropisms of HIF-1α on proliferation, migration, and invasion, its activation would be consequential to tumor growth and metastasis. In addition, HIF-1 can activate vascular endothelial growth factor (VEGF) gene transcription, which may induce intratumoral angiogenesis, further facilitating tumor growth [1]. HIF-1α is thus a critical target for the prevention of cancer progression and distant metastasis. Extensive efforts have been devoted to modulate HIF-1α so that its oncogenic transcription activity can be targeted for cancer therapy.

Newly synthesized HIF-1α is rapidly degraded via the von Hippel-Lindau tumor suppressor (pVHL)-dependent ubiquitin-proteasome pathway [1, 3], which is mediated by...
the hydroxylation of proline residues (Pro402 and Pro564) within the oxygen-dependent degradation (ODD) domain of HIF-1α by a group of prolyl hydroxylases (PHDs) [4]. Factor-inhibiting HIF-1 (FIH-1) suppresses HIF-1 transcription activity through the hydroxylation of an asparaginyl residue on HIF-1α [5], thus blocking the association of HIF-1α with its coactivator protein p300 [6]. Under hypoxic conditions, or in cells with pVHL dysfunction, HIF-1α escapes PHD-dependent degradation and accumulates intracellularly. Inhibition of PHD by α-ketoglutarate (a PHD substrate) antagonist—dimethyloxalyglycine (DMOG), iron chelator or cobalt chloride can interrupt rapid HIF-1α degradation in the presence of a normal level of O2 [4].

Aside from the key regulators that include PHDs, pVHL and O2, other factors can modulate HIF-1α level and HIF-1 transcriptional activity in pVHL- and/or O2-independent manners. For example, p53 contains hypoxia-induced HIF-1α accumulation by promoting Mdm2-mediated ubiquitination and proteasomal degradation [7], which is inhibited by a Jun activation domain-binding protein-1 (Jab1) [8]. The molecular chaperone Hsp90 can influence HIF-1α degradation [9]. The integrity and function of mitochondria are essential to HIF-1α accumulation under hypoxic conditions [10, 11], and HIF-1α acetylation can sensitize the protein to pVHL-mediated ubiquitination and degradation [12]. In addition, a variety of small molecules have the capability of inhibiting HIF-1 transcriptional activity, by affecting the synthesis, turnover, heterodimerization, DNA binding, transactivation or signal transduction of the HIF-1α [1].

Fatty acid metabolism is connected to signaling transduction networks in various pathogeneses. In cancer, for example, abnormalities in fatty acid metabolism may contribute to the Warburg effect, cachexia, mitochondrial dysfunction, cancer aggressiveness and so on [13]. For many catalytic enzymes in fatty acid metabolism, the involvement in cancer development and progression can be partly attributed to the second messenger function of the metabolite. The roles of two key enzymes, cyclooxygenase-2 (COX-2) and 15-lipoxygenase-1 (15-LO1), in carcinogenesis are intriguing, since they appear to function differently in the carcinogenesis of colorectal cancer [14]. Following our prior report that prostaglandin E2 (PGE2) could induce HIF-1α synthesis and that the inhibition of COX-2 could suppress HIF-1α and HIF-1 transcriptional activity [15], we sought to define the role of 15-LO1 in the regulation of the HIF-1α/HIF-1 pathway. This study shows that in opposition to the COX-2 enzyme, 15-LO1 promotes HIF-1α turnover and thus suppresses HIF-1 transcriptional activity. The antagonistic modulation of HIF-1α by 15-LO1 versus COX-2 would be an excellent experimental model for investigating the modulation of fatty acid metabolism on cancer development and progression.

### Material and Methods

#### Cells and culture conditions

Human prostate cancer PC-3 cell line and HEK293 cell line were purchased from American Cell Type Collection (Manassas, VA). For hypoxic exposure (1% O2), cells were placed in a sealed modular incubator chamber (Billups-Rothenberg, Del Mar, CA) flushed with a gas mixture containing 1% O2, 5% CO2, and balanced with N2.

#### Antibodies and reagents

Monoclonal anti-HIF-1α and anti-HIF-1β antibodies were from BD Transduction Laboratories (San Jose, CA) or Novus Biologicals (Littleton, CO), respectively. Anti-human recombinant 15-LO1 antibody [16] was a generous gift from Dr. Sigal at the University of California at San Francisco. The polyclonal antibodies against ubiquitin (FL-76) and actin, and monoclonal antibody against Gal4 (DBD; RK5C1) were from Santa Cruz (Dallas, TX). Monoclonal anti-Flag (M2) antibody was from Sigma-Aldrich (St. Louis, MO). Monoclonal anti-pVHL antibody was from BD Pharmingen (San Jose, CA). Polyclonal human anti-human topoisomerase I (TOPO-I) antibody was from Topogen (Port Orange, FL). Polyclonal anti-SP-1 antibody was from GeneKa Biotechnology (Montreal, Que). Linoleic acid was from Cayman Chemical (Ann Arbor, MI), and dissolved in dimethyl sulfoxide immediately after ethanol solvent was evaporated under a gentle stream of nitrogen. Caffeic acid (CA) and cycloheximide (CHX) were from Biomol International (Plymouth, PA). PD146176 (PD) was from Parke-Davis Pharmaceutical Research (Ann Arbor, MI). Dimethyloxalyglycine (DMOG) was from Frontier Scientific (Logan, UT).

#### Plasmids

Plasmids containing a 2707 base pair full-length human 15-LO1 cDNA either in sense (pcDNA 3.1/15-LOS) or antisense (pcDNA 3.1/15-LOAS) were previously described [17]. These plasmids were used in transfection to PC-3 cells with the GenePorter reagent following the manufacturer’s recommended protocol (Gene Therapy Systems, San Diego, CA). Stably transfected clones were selected with G418 (400 µg/mL).

For mutagenesis, the pcDNA 3.1/15-LOS was used as a template in polymerase chain reaction (PCR). Chimeric primers synthesized were A (5’-ACGTGGCGGCGGCGAtg ggtctac tacctccacct c-3’), introducing a 5’ Not I site), B (5’-ACGTGCGGCGGCGGATG ccgcccgcacttgctggcagagc-3’, introducing 5’ Not I and a ATG codon), E (5’-CAGTGAA TTCtagatgcccacacttttcacc-3’, introducing 3’ EcoR I
site), F (5’-ggaattacagctccTGccagaggctggg-3’, introducing G to T mutation in nucleotide 1208), and G (5’-ccagctcctggcccAgagcttattcc-3’, introducing C to A mutation in nucleotide 1208). To make an AE construct containing the wild-type 15-LO1, nucleotide 4–1968 of the coding region was amplified with primers A and E. To make a BE construct of truncated 15-LO1 lacking β-barrel domain, nucleotide 337–1968 was amplified with primers of B and E. To make an AGFE construct containing a 15-LO1 with Arg^{402}→Leu mutation, two parts of the coding region were amplified with primer pairs of A and G, and F and E, respectively. The two fragments were annealed as template and amplified into a single product by primers A and E. The final PCR products were cloned into pcDNA3.1 following appropriate restriction digest, and were confirmed by DNA sequencing analysis with nested primers.

Two HIF-1α expressing plasmids, Flag/HIF-1α and pcDNA3.1/HIF-1α, were constructed by using p3xFLAG-myc-CMV-25 (Sigma-Aldrich) and pcDNA3.1 (Invitrogen, Carlsbad, CA) mammalian expression vectors, respectively, with the human HIF-1α coding sequence inserted into the HindIII/NcoI site. Construction of the plasmids HA-Gal4-HIF-1α ODD (530–652) and HA-Gal4-HIF-1α ODD (P564A) was as previously described [15]. Firefly luciferase expressing plasmids used in the study were previously described as well [15]. Reporter plasmid pBI-GL V6L contains hypoxia response element (HRE) derived from the human c-Kit gene. Control reporter plasmid pTK-RL was from Promega (Madison, WI).

Protein isolation and Western blot analysis
To isolate nuclear proteins, cells were washed with cold phosphate buffered saline (PBS) and recovered by centrifugation at 500g for 5 min at 4°C. Crude nuclear extracts were prepared by resuspending cell pellets in an ice-cold buffer containing 10 mmol/L Tris-HCl, pH 7.5, 1.5 mmol/L MgCl₂, and 10 mmol/L KCl with 2 mmol/L dithiothreitol (DTT). The nuclei were resuspended in centrifugation at 17,000 g for 10 min at 4°C, and supernatant was saved as cytoplasmic fraction. The nuclei were resuspended in ice-cold buffer containing 0.5 mol/L NaCl, 20 mmol/L Tris, pH 7.5, 20% (v/v) glycerol and 1.5 mmol/L MgCl₂ with the cocktail of protease and phosphatase inhibitors, and incubated on a rotator for 30 min at 4°C, before the nuclear protein was harvested by centrifugation at 20,000 g for 30 min at 4°C. To prepare for whole cell lysates, cells were lysed in light protected buffer containing 100 mmol/L potassium phosphate, pH 7.8, and 0.2% (v/v) Triton X-100 supplemented with 2 mmol/L DTT. Protein concentration was determined by the BCA method (Pierce, Rockford, IL). Equal amounts of protein (30 μg) from each sample were used in Western blotting.

Enzyme-linked immunosorbent assay
VEGF was measured by enzyme-linked immunosorbent assay (ELISA) kit from R&D (Minneapolis, MN). Cells seeded onto 6-well plates at a density of 4 × 10⁴ cells per well were incubated for 24 h in complete media, and subjected to treatments in triplicate. Subsequent media were collected for ELISA, while cells were harvested for cell number counting with a TC2 automated cell counter (Bio-Rad, Hercules, CA). Triplicate measurements were made for each sample.

Transient transfection and reporter gene assay
Cells at 75% confluence in six-well plates were transfected in triplicate with the GenePorter Reagent (Gene Therapy Systems). Transfected HEK293 cells for immunoprecipitation were grown in 10-cm culture dishes. For luciferase reporter assays in six-well plates, each well of cells was transfected with 0.1 μg DNA of reporter plasmid pBI-GL V6L or p2.1, and each well of PC-3 cells was transfected with 1 μg reporter plasmid DNA. Control reporter plasmid pTK-RL was used in 0.05 μg/well for HEK293 cells and 0.5 μg/well for PC-3 cells. Twenty-four hours after transfection, the cells were subjected to different treatments before harvested. Luciferase activity was determined with the Dual-Luciferase Reporter System (Promega) on a LUMIstar Galaxy luminometer (BMG Labtechnologies, Durham, NC). Relative luciferase activity was documented by normalizing activity of the experimental reporter (Firefly) to that of the control (Renilla).

RNA isolation and reverse transcription coupled PCR
Total RNA was isolated from cells grown in 10 cm dishes using TRIzol Reagent (Life Technologies, Carlsbad, CA). A one-step and relative quantitative reverse transcription-PCR (RT-PCR) was performed using the Titan One Tube RT-PCR System (Roche Diagnostics, Indianapolis, IN), in a 50-μL volume containing 0.5 μg of total RNA, 0.2 μmol/L primers and 4 μL of 18S internal standard with an 18S primer pair/competimers ratio of 1:3.5 (Ambion, Austin, TX). Primers for detecting HIF-1α were 5’-c tttaagggaaacggtgc-3’ and 5’-cttgaggtcgaggctc-3’.

VEGF was detected by primers 5’-tcgggctccgaaccacat-tg-3’.
and 5′-gccgagctcttcgcttc-3′. The reaction involved an initial incubation at 50°C for 30 min, followed by 30 cycles of 94°C for 30 sec, 60°C for 30 sec and 72°C for 40 sec, with a final elongation at 72°C for 5 min.

**Immunoprecipitation**

Cells were washed with cold PBS and lysed on ice in buffer containing 50 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, 1 mmol/L Ethylenediaminetetraacetic acid (EDTA), and 1% (v/v) Triton X-100 supplemented with the protease and phosphatase inhibitor cocktail. After removing cellular debris by centrifugation at 10,000g for 10 min at 4°C, lysates were precleared by adding 1.0 µg of control IgG together with 20 µL of resuspended volume of agarose conjugate, and incubated at 4°C for 30 min. For each sample, 1 mg protein was immunoprecipitated with 1 µg primary antibody and 40 µL beads, or with antibody agarose conjugate, at 4°C with rotation for 1.5 h. Immunoprecipitates were washed four times in a buffer of 50 mmol/L Tris, pH 7.4, and 150 mmol/L NaCl, and recovered by centrifugation at 1000g at 4°C for 5 min. Immunoprecipitates were washed again in ice-cold PBS, resuspended in 50 µL of 2X SDS buffer, and boiled for 5 min. The 30-µL aliquots were analyzed by SDS-PAGE and Western blotting.

**Ubiquitination assays**

For the in vivo ubiquitination assay, cells at 75% confluence on 10-cm dishes were transfected with mammalian expression plasmids. Twenty-four hours after transfection, the cells were subjected to treatments as designed, and were subjected to an additional treatment with 5 µmol/L MG132 for another 4 h. Cells were washed with cold PBS and lysed in cold buffer containing 50 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, 1 mmol/L EDTA, and 1% (v/v) Triton X-100. Immunoprecipitation and Western blotting were performed with appropriate antibodies.

For in vitro ubiquitination assay, HIF-1α ODD trans- lates was generated in vitro from the Gal4-HIF-1α ODD (530-652) plasmid with the TNT T7 coupled transcription/translation system (Promega), in the presence of 2 µCi 35S-methionine. Briefly, cells were incubated in ice-cold hypotonic buffer (20 mmol/L Tris, pH 7.4, 5 mmol/L MgCl2, and 8 mmol/L KCl, with 1 mmol/L DTT and plus inhibitor cocktail) for 15 min, and were subjected to three cycles of freeze and thaw. After centrifugation at 14,000g for 5 min, the supernatant was ultra centrifuged at 100,000g for 4 h, and was aliquoted and stored at −80°C. 35S-labeled trans- lates (2 µL) were incubated in the presence of S100 extracts (100 µg) supplemented with 8 µg/µL ubiquitin (Sigma-Aldrich), 100 ng/µL ubiquitin aldehyde (BostonBiochem, Cambridge, MA) and energy-regenerating system (20 mmol/L Tris, pH 7.4, 2 mmol/L ATP, 5 mmol/L MgCl2, 40 mmol/L creatine phosphate and 0.5 µg/µL creatine kinase) in a 40-µL volume for 1.5 h at 30°C. Products were immunoprecipitated with anti-Gal4 and resolved by SDS-PAGE.

**Data analysis**

Experiments presented in the figures were representative of reproducible experiments of 2 or more. Data of luciferase activity were the average of triplicates. Densitometry quantification in Figure 3 was performed using the Bio-Rad image analysis system. Statistical analysis in Figure 1E was performed using a 2-sample t test. A P < 0.05 was considered statistically significant.

**Results**

**HIF-1α and HIF-1 transcriptional activity are modulated in cells with differential 15-LO1 expression**

Forced expression of 15-LO1 by stable transfection in human prostate cancer PC-3 cells has been previously reported [17], resulting in a marked increase in 15-LO1 enzymatic activity. We transfected PC-3 cells with the same expression constructs to isolate stably transfected clones. Transfection with 15-LO1 coding sequence in sense orientation resulted in LOX-H clones with 15-LO1 overexpression, while transfection with the same sequence in antisense orientation led to the isolation of LOX-L clones that showed decreased 15-LO1 levels relative to the control clones. Following confirmation of the 15-LO1 expression by Western blotting, the same blots were used to examine the effect of 15-LO1 on HIF-1α level.

Under standard culture conditions (21% O2, normoxia), basal HIF-1α levels were consistently lower in LOX-H cells and higher in LOX-L cells as compared with PC-3 cell control clones that expressed a constitutive level of HIF-1α (Fig. 1A). The differences existed when cells were treated with CoCl2, which inhibits HIF-1α proteasomal degradation. Other proteins, such as HIF-2α, HIF-1β, SP-1 and TOPO-1, did not present similar dynamics. Two 15-LO1 inhibitors, CA [19] and PD146176 (PD) [20], increased HIF-1α in a dose-dependent fashion in PC-3 control cells that express a minimal level of 15-LO1 activity, and in LOX-H cells that express a high level of 15-LO1 activity. The observed HIF-1α inhibition seemed to be mediated by enzymatic activity of the 15-LO1.

Because 15-LO1 overexpression and inhibition resulted in different HIF-1α levels, representing a novel mechanism by which lipid metabolism modulates HIF-1 signaling, we next investigated biologic significance of the
15-LO1 modulation by measuring HIF-1 transcriptional activity and HIF-1 downstream gene (VEGF) expression. We found that HIF-1α-dependent transcriptional activity was markedly higher in LOX-L cells than in LOX-H cells not only under normoxia but also under hypoxia (1% O2) or in cells treated by CoCl2 (Fig. 1B). The differential luciferase activity was in full agreement with the changes in HIF-1α level in those cells (Fig. 1C). The inhibitory effect of 15-LO1 on HIF-1 was confirmed by alternative methods. As demonstrated by RT-PCR analysis, the differences in VEGF gene expression at mRNA level existed between LOX-H and LOX-L cells, where hypoxia induced VEGF121 to a greater extent than the other isoforms (Fig. 1D) in agreement with previous findings [21]. The differences in VEGF expression between LOX-H and LOX-L cells were also detected at translational level. Determined by ELISA, VEGF secretion was consistently lower in LOX-H cells compared to LOX-L cells under normoxia or hypoxia with statistically significant differences (Fig. 1E). Above results indicate that forced overexpression of 15-LO1 decreases HIF-1α with a resultant reduction in HIF-1 transcriptional activity and HIF-1 target VEGF gene expression, whereas inhibition of 15-LO1 does the opposite, and furthermore, 15-LO1 enzyme activity is likely involved in the process.

Attenuation of 15-LO1 restores functional HIF-1α

To further establish the role of 15-LO1 in regulating HIF-1α expression, the site-directed mutagenesis or truncation of human 15-LO1 was carried out to attenuate 15-LO1 function. Two sites that are critical for 15-LO1 function were targeted: Arg402 in the C-terminal catalytic domain [22] and

Figure 1. Stable 15-LO1 transfection altered HIF-1α and HIF-1 transcriptional activity. (A) Western blotting analysis of crude nuclear extracts from PC-3, LOX-H and LOX-L cells. The cells in six-well plates at 70% confluence were subjected to overnight serum starvation, and treated with different reagents in serum-free media for 16 h before harvest. 15-LO1 inhibitors Caffeic acid and PD146176 were dissolved in dimethyl sulfoxide (DMSO). DMSO volumes were <0.5% (v/v) in culture medium. Immunoblots were repeatedly stripped and probed. (B) Transient transfection and reporter gene assays were conducted in LOX-H and LOX-L cells. After transfection for 24 h, cells were cultured for additional 16 h under normoxic or hypoxic conditions, or treated with CoCl2 before harvest. The figure represents mean ± SD of triplicate of one experiment. (C) Whole cell lysates in the transient transfection assay in B were analyzed for HIF-1α expression by Western blot. Similar results were shown in triplicate of one experiment, and reproduced in two more repeats. (D) Total RNA in LOX-H and LOX-L cells was analyzed for transcription of the VEGF (upper panel) and HIF-1α (lower panel) gene by RT-PCR after cells were subjected to normoxia or hypoxia for 24 h. DNA standards and the products of major VEGF isoforms are indicated. (E) Culture medium in experiment D was assayed for VEGF production with ELISA. Bars indicate standard deviations of triplicates and asterisk (*) denotes statistical significance compared to those in LOX-H cells (P < 0.05).
\[\text{\(\beta\)-barrel domain in the N-terminal} \] [23]. An alternative mammalian expression vector (p3\(\times\)FLAG-myc-CMV-25) was used in constructing the mutants. Generated expression constructs included a wild-type control with the 1989 bp cDNA covering the full-length of the 15-LO1 coding sequence (the AE construct), a mutant with \(\beta\)-barrel domain truncation (the BE construct), and another carrying Arg\(^{402}\) \(\rightarrow\) Leu replacement (the AGFE construct) (Fig. 2A).

In transient transfection assays, the AE (wild-type 15-LO1) inhibited co-expressed HIF-1\(\alpha\) levels in HEK-293 cells (Fig. 2B), and the inhibition was in a similar fashion as that observed in PC-3 cells with stable 15-LO1 overexpression that was stably transfected with the original expression construct carrying the 2707 bp cDNA in a different mammalian expression vector, pcDNA3.1. Importantly, transfection with the mutants, BE or AGFE,
failed to decrease HIF-1α as compared with the parallel transfection with the AE (Fig. 2C). Consistent with the HIF-1α level, HIF-1 transcriptional activity was dynamically modulated among these constructs (Fig. 2D and E). Accordingly, co-transfection of the AE with luciferase reporter to HEK-293 cells resulted in marked inhibition of the reporter gene activity under different conditions (Fig. 2E). In comparison, the inhibitory effect was markedly compromised when either the BE or AGFE mutant was applied (Fig. 2D). These results not only confirm the inhibitory effect of 15-LO1 on HIF-1α but also indicate that the functional structures of 15-LO1 are critical for the enzyme to exert the inhibitory effect.

**Inhibition of 15-LO1 activity decreases the rate of HIF-1α degradation**

HIF-1α could be modulated at several levels [1]. In order to determine whether or not the modulation by 15-LO1 occurred at transcriptional level, we analyzed HIF-1α mRNA levels by RT-PCR in LOX-H and LOX-L cells. HIF-1α mRNA expression showed no marked differences between the two cell types under normoxic or hypoxic conditions (Fig. 1D, lower panel), and no differences between LOX-H cells treated with and without 15-LO1 inhibitors (data not shown). These results suggest that the modulation is not at transcriptional level. We next examined whether the modulation took place at posttranslational level, by determining the rate of HIF-1α decay. PC-3 cells are known to express a low basal level of 15-LO1 [17] and relatively high basal level of HIF-1α [15], facilitating a convenient tracking of degradation.

PC-3 cells pretreated with 15-LO1 inhibitor CA for 22 h were blocked for protein synthesis by cycloheximide (CHX). Nuclear extracts and cytoplasmic fractions from the treated cells were subjected to HIF-1α decay analysis. Compared to the vehicle control, PC-3 cells treated with CA contained elevated levels of HIF-1α both in the nuclear and cytoplasmic compartments (Fig. 3). Importantly, the rate of HIF-1α degradation appeared to be slower in the presence of CA treatment. The effect of CA was specific to the HIF-1α subunit, as HIF-1β remained constant throughout the study period. These results indicate that the enzymatic activity of 15-LO1 exerts an inhibitory effect specifically on the HIF-1α subunit, likely by accelerating its degradation.

**15-LO1 promotes HIF-1α ubiquitination and proteasomal degradation in normoxia**

Protein degradation is a critical regulatory mechanism controlling HIF-1α homeostasis [1], mainly through the machinery of ubiquitination-directed proteasomal degradation [1, 3, 4, 18]. To investigate whether 15-LO1 could affect this machinery, we conducted in vivo and in vitro ubiquitination assays following previously reported methodology [18]. In transient co-transfection in HEK293 cells, 15-LO1 facilitated HIF-1α ubiquitination (Fig. 4A), which was attenuated by 15-LO1 inhibitor PD146176, but enhanced by 15-LO1 substrate linoleic acid (Fig. 4B). The results confirm the involvement of 15-LO1 enzymatic activity and suggest potential involvement of 15-LO1 metabolites.

In further studies defining target site of the inhibitory effect, 15-LO1 promoted the ubiquitination of a HIF-1α polypeptide containing ODD domain (530–652) (Fig. 4C). The accumulation of ubiquitinated polypeptide was decreased when proline residue Pro564 was mutated to alanine (Fig. 4C). Moreover, we confirmed the results by examining ubiquitination rate of in vitro synthesized HIF-1α. Proteins synthesized with cell-free transcription coupled translation are mostly in a naïve state, free of
modification and degradation. A radiolabeled HIF-1α polypeptide containing ODD domain (530–652) was synthesized in vitro and used as ubiquitination target, and S100 proteins from PC-3 derivative clones were used as the source of ubiquitin. In these assays, ubiquitination was consistently more pronounced with the addition of S100 extracts from LOX-H rather than LOX-L cells (Fig. 4D). These results suggest that 15-LO1 promotes HIF-1α ubiquitination and that this process requires an intact HIF-1α ODD domain containing Pro564. The enhanced HIF-1α ubiquitination by 15-LO1 was unlikely due to an increasing level of pVHL, since the levels of pVHL expression in LOX-H and LOX-L cells were identical (Fig. 4E). On the other hand, 15-LO1-mediated HIF-1α degradation could be blocked by 26S proteasome inhibitor MG132 (Fig. 4F), or in the presence of the PHD inhibitor DMOG. Pro564 hydroxylation, ubiquitination, and 26S proteasome system are thus essential for 15-LO1-mediated HIF-1α degradation in normoxia.

**Discussion**

In this study, we investigated the role of 15-LO1 in modulating HIF-1α homeostasis by altering the amount and the enzymatic activity of 15-LO1 in cultured cells. Using multiple molecular methods, we demonstrated that 15-LO1 decreased HIF-1α and suppressed HIF-1 transcriptional activity. This study thus unveiled a link between lipid metabolism and transcriptionally controlled hypoxic response, a previously unrecognized regulation between two seemingly independent aspects of cellular physiology. HIF-1α inhibition was determined to be at posttranslational level, through promoting ubiquitination and degradation. Since ubiquitin-directed degradation is the major
biological thoroughfare to an efficient purge of regulatory proteins following the stress response [24], further investigation is warranted to assess whether 15-LO1 plays a significant role in fine-tuned homeostatic regulation. Most importantly, we were able to show that the enzymatic activity of 15-LO1 was critical in above mentioned inhibitory effects, as the inhibition could be reversed by antagonizing the enzyme, while substrate of 15-LO1 displayed differential inhibitory effects on 15-LO1-mediated HIF-1α ubiquitination as demonstrated in Figure 4B. In fact, addition of 15-LO1 substrate linoleic acid to LOX-H cells was also shown to be able to reduce HIF-1α (data not shown), indicating the metabolites derived from 15-LO1 enzymatic activity could contribute to the inhibitory process. This work has for the first time offered an exciting strategy for modulating hypoxic response indirectly by pharmacological adjustment of lipid metabolism. 15-LO1 causes HIF-1α instability by increasing HIF-1α ubiquitination and hence increasing the rate of degradation. Because the S100 fraction from 15-LO1-overexpressing cells was detected with increased ubiquitination activity, the mechanism underlying the inhibitory effect on HIF-1α could be complex. Nonetheless, several clues from this study may direct further investigation. First, the enzymatic activity of 15-LO1 is required for inhibition. This is not only supported by changes in HIF-1α level in cells with different amounts of 15-LO1 or cells treated with 15-LO1 inhibitors but also supported by mutational assay in which the mutation of Arg402 residue in the C-terminal catalytic domain of 15-LO1 results in restoration of HIF-1α. The Arg402 residue is critical for 15-LO1 enzymatic activity since it is required for substrate binding. Specifically, the activity in the substrate binding of the Arg402 → Leu mutant is only 5% of the wild-type activity against arachidonic acid or linoleic acid, which corresponds to the markedly lowered enzymatic reaction rate in the mutant [22]. Second, the function of the N-terminal β-barrel domain is independently involved, because 15-LO1 with an N-terminal β-barrel domain truncation is still able to restore HIF-1α in the presence of an intact C-terminal catalytic domain. The N-terminal β-barrel domain of 15-LO1 is not thought to be essential for catalytic activity, but is able to mediate intracellular membrane binding [25]. The ability to bind intracellular membrane is required for 15-LO1’s intracellular organelle degradation function, and this function is important for the removal of aged mitochondria [23, 26]. Third, the differential HIF-1α levels and differential HIF-1 transcriptional activity between cells with forced overexpression of 15-LO1 (LOX-H cells) and cells with 15-LO1 knockdown (LOX-L cells) can be seen in both normoxic and hypoxic conditions, and in cells treated by CoCl2. This observation suggests that 15-LO1 may be capable of inducing HIF-1α turnover through additional mechanisms that are different from the classic pathway, O2-mediated HIF-1α ubiquitination/degradation. It is the authors’ opinion that 15-LO1 may exert an affect as a co-substrate or an enhancer in the process of HIF-1α degradation even under low oxygen tension or in the presence of CoCl2. The intracellular organelle degradation capability of 15-LO1, particularly degradation of mitochondria [23, 26], is likely to play a role in the reduction in HIF-1α in LOX-H cells in such a situation since intact and functional mitochondria are required for HIF-1α accumulation under hypoxia [10, 11]. In addition, direct physical interaction between 15-LO1 and HIF-1α was not identified in our experiments (data not shown). The effects of 15-LO1 on reducing HIF-1α expression and HIF-1 transcriptional activity are not limited to the prostate cancer PC-3 cells. In a colon cancer cell line HCT116 with forced 15-LO1 stable expression (generous gift from Dr. Thomas Eling of NIEHS, NIH), similar results were demonstrated and were consistently reproducible (data not shown). Further investigations are warranted to understand the more detailed molecular mechanisms.

Studies from past decades have linked oxidative metabolism of polyunsaturated fatty acids to a variety of pathogenesis, including tumorigenesis. Two major classes of enzymes are involved in this process, cyclooxygenase, and lipoxygenase. Many years ago it was proposed that there exists a balance between the procarcinogenic role of the arachidonic acid/COX-2/PGE2 pathway and the anticarcinogenic role of the linoleic acid/15-LO1/13-S-HODE pathway in colon cancer [14]. Recently, the same group has further demonstrated the tumor suppressor function of 15-LO1 in transgenic mouse by tissue-specific expression of human 15-LO1 [27]. Our prior studies have shown that PGE2 induces HIF-1α while COX-2 inhibitor reduces it [15]. In our experimental system, a similar balance seems evident between the COX-2/PGE2 pathway and the linoleic acid/15-LO1 pathway in the regulation of HIF-1α.

The actual role of 15-LO1 in carcinogenesis, however, remains elusive despite much research effort over the last decade. Both anticarcinogenic and procarcinogenic roles have been proposed [17, 27–35]. In agreement with its tumor suppressor function, 15-LO1 is downregulated in many human cancer types in comparison with their benign counterparts [36–40], whereas it is overexpressed in prostate cancer and its precursors [41]. Similarly to its role in colorectal carcinogenesis [27], 15-LO1 appears to function as a tumor suppressor in many other organ systems. For example, overexpression of 15-LO1 inhibits tumor formation and metastasis in breast or lung cancer transgenic mouse models [30], and it significantly prolongs survival in rats with glioma via inducing lipid peroxidation [32]. In contrast, 15-LO1 appears to promote
tumorigenesis and tumor progression in prostate cancer [17, 33, 34] and malignant melanoma [35]. Regarding the role of 15-LO1 in VEGF regulation and angiogenesis, results are also controversial. Overexpression of 15-LO1 in PC-3 prostate cancer cells increases angiogenesis and VEGF secretion in xenografts [17], which is contradictory to results found in this in vitro study based on the same prostate cancer cell line. In nontumor models, Yao et al. have recently found that the 15-LO1 metabolite, 15-HETE, can induce HIF-1α expression and HIF-1α transcriptional activity under both normoxic and hypoxic conditions [42]. However, 15-LO1 has been demonstrated to exert an antiangiogenic effect by inhibiting VEGF-A expression in rabbit skeletal muscle [43], mouse ischemic retinopathy [44], and hypoxia-induced retinal microvascular endothelial cells [45]. Taken altogether, the actual role of 15-LO1 in angiogenesis and carcinogenesis is more complicated than we thought. It may be both context-dependent and content-dependent. For example, it may be dependent on the environment, species, organ, tissue, cell type, major metabolite, and/or dependent on which substrate (arachidonic acid or linoleic acid), enzyme (cyclooxygenase or lipoxygenase) or isozyme (15-LO1 or other LOs) are dominant in the cells and microenvironments.

In summary, 15-LO1 is able to promote HIF-1α turnover and to suppress VEGF expression in cultured cells based on forced stable overexpression or transient transfection, whereas 15-LO1 inhibition reverses above effects. Taken together, the results from our prior and current studies thus confirm that the linoleic acid/15-LO1 and COX-2/PGE2 pathways have different impacts on the regulation of the HIF-1α/HIF-1/VEGF system. The oxidative metabolism of polyunsaturated fatty acid is thought to play a critical role in turning on “metabolic switch” in cancer cells [13]. Our findings support that some delicate elements of fatty acid metabolism have “Yin” or “Yang” impact on pathogenic angiogenesis or cancerous “angiogenic switch”, implying potential therapeutic and critical correction of the manuscript.

Acknowledgments

We thank Drs. Michael Ohh and William G. Kaelin (Dana-Farber Cancer Institute, Harvard University) for their generous gifts of the plasmids HA-Gal4-HIF-1α ODD, Dr. Erwin van Meir (Winship Cancer Institute, Emory University) for his generous gift of the plasmids pBl-GL V6L, and Dr. Thomas Eling (NIEHS, NIH) for his generous gift of HCT116 cell line. We thank Ms. Margaret Willard for daily laboratory maintenance. We thank Drs. Jay Umbreit and Hyunsuk Shim (Winship Cancer Institute, Emory University), and Dr. Lorna Rodriguez (Rutgers Cancer Research of New Jersey) for reading and critical correction of the manuscript.

Conflict of Interest

None declared.

References

1. Semenza, G. L. 2012. Hypoxia-inducible factors in physiology and medicine. Cell 148:399–408.
2. Zhong, H., A. M. De Marzo, E. Laughner, M. Lim, D. A. Hilton, D. Zagzag, et al. 1999. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 59:5830–5835.
3. Kaelin, W. G., Jr., and P. J. Ratcliffe. 2008. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30:393–402.
4. Epstein, A. C., J. M. Gleadle, L. A. McNeill, K. S. Hewitson, J. O’Rourke, D. R. Mole, et al. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43–54.
5. Mahon, P. C., K. Hirota, and G. L. Semenza. 2001. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1α transcriptional activity. Genes Dev. 15:2675–2686.
6. Lando, D., D. J. Peet, D. A. Whelan, J. J. Gorman, and M. L. Whitelaw. 2002. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295:858–861.
7. Ravi, R., B. Mookerjee, Z. M. Bhujwalla, C. H. Sutter, D. Artemov, Q. Zeng, et al. 2000. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1αalpha. Genes Dev. 14:34–44.
8. Bae, M. K., M. Y. Ahn, J. W. Jeong, M. H. Bae, Y. M. Lee, S. K. Bae, et al. 2002. Jab1 interacts directly with HIF-1alpha and regulates its stability. J. Biol. Chem. 277:9–12.
9. Isaacs, J. S., Y. J. Jung, E. G. Mimnaugh, A. Martinez, F. Sohn, M. H. Bae, et al. 2002. Regulation and turnover of the hypoxia-inducible factor 1α alpha-degradative pathway. J. Biol. Chem. 277:29936–29944.
10. Agani, F. H., P. Pichiule, J. C. Chavez, and J. C. LaManna. 2000. The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia. J. Biol. Chem. 275:35863–35867.
11. Chandel, N. S., E. Maltepe, E. Goldwasser, C. E. Mathieu, M. C. Simon, and P. T. Schumacker. 1998. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc. Natl. Acad. Sci. USA 95:11715–11720.
12. Jeong, J. W., M. K. Bae, M. Y. Ahn, S. H. Kim, T. K. Sohn, M. H. Bae, et al. 2002. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111:709–720.
13. Carracedo, A. 2013. Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 13:227–232.
14. Shureiqi, I., and S. M. Lippman. 2001. Lipoygenase modulation to reverse carcinogenesis. Cancer Res. 61:6307–6312.
15. Zhong, H., M. Willard, and J. Simons. 2004. NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. Int. J. Cancer 112:585–595.
16. Sigal, E., D. Grunberger, E. Highland, C. Gross, R. A. Dixon, and C. S. Craik. 1990. Expression of cloned human reticulocyte 15-lipoygenase and immunological evidence that 15-lipoygenases of different cell types are related. J. Biol. Chem. 265:5113–5120.
17. Kelavkar, U. P., J. B. Nixon, C. Cohen, D. Dillehay, T. E. Eling, and K. F. Badr. 2001. Overexpression of 15-lipoygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 22:1765–1773.
18. Ohh, M., C. W. Park, M. Ivan, M. A. Hoffman, T. Y. Kim, L. E. Huang, et al. 2000. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2:423–427.
19. Gleason, M. M., C. J. Rojas, K. S. Learm, M. H. Perrone, and G. E. Bilder. 1995. Characterization and inhibition of 15-lipoygenase in human monocyes: comparison with soybean 15-lipoygenase. Am. J. Physiol. 268:C1301–C1307.
20. Sendobry, S. M., J. A. Cornicelli, K. Welch, T. Bocan, B. Tait, B.K. Trivedi, et al. 1997. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoygenase inhibitor lacking significant antioxidant properties. Br. J. Pharmacol. 120:1199–1206.
21. Scott, P. A., J. M. Gleadle, R. Bicknell, and A. L. Harris. 1998. Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines. Int. J. Cancer 75:706–712.
22. Gan, Q. F., M. F. Browner, D. L. Sloane, and E. Sigal. 1996. Defining the arachidonic acid binding site of human 15-lipoygenase. Molecular modeling and mutagenesis. J. Biol. Chem. 271:25412–25418.
23. van Leyen, K., R. M. Duvoisin, H. Engelhardt, and M. Wiedmann. 1998. A function for lipoygenase in programmed organelle degradation. Nature 395:392–395.
24. Kelly, S. M., J. K. Vanslyke, and L. S. Musil. 2007. Regulation of ubiquitin-proteasome system mediated degradation by cytosolic stress. Mol. Biol. Cell 18:4279–4291.
25. Walther, M., M. Anton, M. Wiedmann, R. Fletterick, and H. Kuhn. 2002. The N-terminal domain of the reticulocyte-type 15-lipoygenase is not essential for enzymatic activity but contains determinants for membrane binding. J. Biol. Chem. 277:27360–27366.
26. Schewe, T., W. Halangk, C. Hiebsch, and S. Rapoport. 1977. Degradation of mitochondria by cytosolic factors in reticulocytes. Acta Biol. Med. Gen. 36:563–572.
27. Zuo, X., Z. Peng, Y. Wu, M. J. Moussalli, X. L. Yang, Y. Wang, et al. 2012. Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice. J. Natl. Cancer Inst. 104:709–716.
28. Kamitani, H., M. Geller, and T. Eling. 1998. Expression of 15-lipoygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation. J. Biol. Chem. 273:21569–21577.
29. Shureiqi, I., D. Chen, J. J. Lee, P. Yang, R. A. Newman, D. E. Brenner, et al. 2000. 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J. Natl. Cancer Inst. 92:1136–1142.
30. Harats, D., B. Ben-Shushan, H. Cohen, A. Gonen, I. Barshack, I. Goldberg, et al. 2005. Inhibition of carcinogenesis in transgenic mouse models over-expressing 15-lipoygenase in the vascular wall under the control of murine preproendothelin-1 promoter. Cancer Lett. 229:127–134.
31. Cimen, I., S. Tuncay, and S. Banerjee. 2009. 15-Lipoygenase-1 expression suppresses the invasive properties of colorectal carcinoma cell lines HCT-116 and HT-29. Cancer Sci. 100:2283–2291.
32. Viita, H., A. Pacholska, F. Ahmad, J. Tietäväinen, J. Naarala, A. Hyvärinen, et al. 2012. 15-Lipoygenase-1 induces lipid peroxidation and apoptosis, and improves survival in rat malignant glioma. In Vivo 26:1–8.
33. Kelavkar, U. P., W. Glasgow, S. J. Olson, B. A. Foster, and S. B. Shappell. 2004. Overexpression of 12/15-lipoygenase, an ortholog of human 15-lipoygenase-1, in the prostate tumors of TRAMP mice. Neoplasia 6:821–830.
34. Sen, M., K. McHugh, J. Hutzley, B. J. Philips, R. Dhir, A. V. Parwani et al. 2006. Orthotopic expression of human 15-lipoygenase-1 expression in the dorsolateral prostate of normal wild-type C57BL/6 mouse causes PIN-like lesions. Prostaglandins Other Lipid Mediat. 81:1–8.
35. Wang, X., X. Peng, Y. Wu, J. J. Lee, P. Yang, J. W. I. W. B. J. P. L. A.2005. Inhibition of 15-lipoygenase-1 expression reduces IAP degradation by cytosolic stress. Mol. Biol. Cell 18:4279–4291.
36. Moussalli, M. J., Y. Wu, X. Zuo, X. L. Yang, I. I. Wistuba, M. G. Raso, et al. 2011. Mechanistic contribution of ubiquitous 15-lipoygenase-1 expression loss in cancer cells to terminal cell differentiation evasion. Cancer Prev. Res. (Phila) 4:1961–1972.
37. Philips, B. J., R. Dhir, J. Hutzley, M. Sen, and U. P. Kelavkar. 2008. Polyunsaturated fatty acid metabolizing 15-Lipoygenase-1 (15-LO-1) expression in normal and tumorigenic human bladder tissues. Appl. Immunohistochem. Mol. Morphol. 16:159–164.
38. Hennig, R., T. Kehl, S. Noor, X. Z. Ding, S. M. Rao, F. Bergmann, et al. 2007. 15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. Neoplasia 9:917–926.

39. Jiang, W. G., G. Watkins, A. Douglas-Jones, and R. E. Mansel. 2006. Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer. Prostaglandins Leukot. Essent. Fatty Acids 74:235–245.

40. Heslin, M. J., A. Hawkins, W. Boedefeld, J. P. Amoletti, A. Frolov, R. Soong, et al. 2005. Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. Ann. Surg. 241:941–946; discussion 946–947.

41. Kelavkar, U., C. Cohen, T. Eling, and K. Badr. 2002. 15-lipoxygenase-1 overexpression in prostate adenocarcinoma. Adv. Exp. Med. Biol. 507:133–145.

42. Yao, L., X. Nie, S. Shi, S. Song, X. Hao, S. Li, et al. 2012. Reciprocal regulation of HIF-1 alpha and 15-LO/15-HETE promotes anti-apoptosis process in pulmonary artery smooth muscle cells during hypoxia. Prostaglandins Other Lipid Mediat. 99:96–106.

43. Viita, H., J. Markkanen, E. Eriksson, M. Nurminen, K. Kinnunen, M. Babu, et al. 2008. 15-lipoxygenase-1 prevents vascular endothelial growth factor A- and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels, NO bioactivity, and downregulation of VEGF receptor 2 expression. Circ. Res. 102:177–184.

44. Li, Z., T. He, K. Du, Y. Q. Xing, Y. Yan, Z. Chen, et al. 2012. Overexpression of 15-lipoxygenase-1 in oxygen-induced ischemic retinopathy inhibits retinal neovascularization via downregulation of vascular endothelial growth factor-A expression. Mol. Vis. 18: 2847–2859.

45. Yan, Y., T. He, Y. Shen, X. Chen, B. Diao, Z. Li, et al. 2012. Adenoviral 15-lipoxygenase-1 gene transfer inhibits hypoxia-induced proliferation of retinal microvascular endothelial cells in vitro. Int. J. Ophthalmol. 5:562–569.